Canopy Growth vs. Tilray Brands: Which Cannabis Stock Is a Better Buy in 2026?

The cannabis industry is shifting from pure cultivation to global consumer brands, leading to the need to compare companies like Canopy Growth (CGC) and Tilray Brands (TLRY). Canopy Growth focuses on Canadian adult-use markets and European medical sales, while Tilray diversifies into craft beverages and wellness to reduce reliance on volatile cannabis prices.

In 2026, Canopy Growth generated $199.5 million in revenue, a 5.8% increase from the previous year, but reported a net loss of $184.3 million, resulting in a negative operating margin of 92.4%. The company's debt-to-equity ratio is approximately 0.4x, and its current ratio is about 3.3x. Free cash flow for the year was nearly -$48.9 million.

Tilray Brands, on the other hand, reported revenue of $915.5 million in 2026, an 18.8% decrease from the previous year, with a net loss of $122.6 million, or a negative 13.4% net margin. Tilray's debt-to-equity ratio is approximately 0.2x, and its current ratio is nearly 2.2x. Free cash flow for the year was close to -$102.1 million.

Both companies face regulatory risks, such as restatements of prior financial data and potential delisting threats. Tilray operates in international jurisdictions with high regulatory hurdles and competition from rivals and the illicit market. Despite these challenges, Tilray's larger scale, diversified revenue streams, and progress in profitability make it the more attractive option between the two stocks.